Status:
COMPLETED
Development of the Oncology Opportunity Cost Assessment Tool
Lead Sponsor:
Thomas Jefferson University
Conditions:
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Eligibility:
MALE
18+ years
Brief Summary
This study develops and tests an instrument to measure opportunity costs called the Oncology Opportunity Cost Assessment Tool (OOCAT) in cancer patients. Patients experience significant costs, both di...
Eligibility Criteria
Inclusion
- Treated for cancer at one of the 3 participating sites (Jefferson Center City, Jefferson Methodist Hospital, Jefferson Abington)
- English speaking
- Able to attend and participate in a focus group
Exclusion
- Treated at a Jefferson site other than the ones mentioned
- Non-English Speaking
Key Trial Info
Start Date :
November 21 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04694911
Start Date
November 21 2019
End Date
July 31 2021
Last Update
April 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107